Evommune (EVMN) – Analysts’ Recent Ratings Updates

Evommune (NYSE: EVMN) recently received a number of ratings updates from brokerages and research firms:

• 9/18/2026 – Evommune had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 9/11/2026 – Evommune was downgraded by Weiss Ratings from “sell (d-)” to “sell (e+)”.
• 9/9/2026 – Evommune was given a new $30.00 price target by Stifel Nicolaus.
• 9/9/2026 – Evommune was given a new $18.00 price target by Raymond James Financial, Inc..
• 9/9/2026 – Evommune had its price target lowered by Leerink Partners from $28.00 to $22.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Evommune had its price target lowered by Royal Bank Of Canada from $29.00 to $21.00. They now have an “outperform” rating on the stock.
• 9/9/2026 – Evommune had its “neutral” rating reaffirmed by HC Wainwright.
• 8/26/2026 – Evommune is now covered by Needham & Company LLC. They set a “buy” rating and a $28.00 price target on the stock.
• 8/7/2026 – Evommune had its price target lowered by Royal Bank Of Canada from $30.00 to $29.00. They now have an “outperform” rating on the stock.
• 8/3/2026 – Evommune had its “neutral” rating reaffirmed by HC Wainwright.

Insider Buying and Selling

In other news, Director Arthur S. Kirsch acquired 10,000 shares of the company’s stock in a transaction on Tuesday, July 7th. The shares were bought at an average price of $13.30 per share, with a total value of $133,000.00. Following the completion of the acquisition, the director owned 10,000 shares in the company, valued at $133,000. This trade represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 31.10% of the stock is owned by corporate insiders.

Evommune, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for immune-mediated inflammatory diseases. The company uses its research platform to identify and advance therapies designed to address underlying mechanisms of chronic inflammation rather than only managing symptoms.

Evommune’s pipeline has included soquelitinib, an oral, selective inhibitor of inducible T-cell kinase (ITK) being investigated for inflammatory and immune-related conditions. The company’s development programs have focused on diseases such as atopic dermatitis and other dermatologic or systemic inflammatory disorders, although programs and indications may change as clinical research progresses.

The company’s activities are centered on drug discovery and clinical development, with potential commercialization dependent on successful clinical trials and regulatory approvals.